81 related articles for article (PubMed ID: 21599513)
21. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
[TBL] [Abstract][Full Text] [Related]
22. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
23. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M
Breast Cancer Res Treat; 2010 Jan; 119(2):315-23. PubMed ID: 19247830
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
25. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
[TBL] [Abstract][Full Text] [Related]
26. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
27. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
28. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
29. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
30. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
31. The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy.
Harris EE; Hwang WT; Lee EA; Cengel KA; Feldman MD; Demichele A; Kao G; Solin LJ
Breast J; 2006; 12(5):431-6. PubMed ID: 16958961
[TBL] [Abstract][Full Text] [Related]
32. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
[TBL] [Abstract][Full Text] [Related]
33. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
34. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
[TBL] [Abstract][Full Text] [Related]
36. Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases.
Guan B; Wang H; Cao S; Rao Q; Wang Y; Zhu Y; Shi Q; Yin H; Wang X; Zhou X
Ann Diagn Pathol; 2011 Aug; 15(4):225-32. PubMed ID: 21396871
[TBL] [Abstract][Full Text] [Related]
37. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
38. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
39. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
40. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
